VivoSim Labs, INC. reported fiscal 2026 results showing essentially flat revenue of $0.13M versus $0.14M in FY 2025, while the company recorded a consolidated net loss of $13.843M for FY 2026 compared with a net loss of $2.488M in FY 2025; diluted loss per share was $(5.35) for FY 2026 versus $(1.70) in FY 2025.
Financial Highlights
- Revenue was $0.13M for FY 2026, essentially flat versus $0.14M in FY 2025 (royalty-driven).
- Net income (loss) was a loss of $13.843M for FY 2026 versus a loss of $2.488M for FY 2025 (consolidated).
- Diluted earnings per share was a loss of $(5.35) for FY 2026 versus $(1.70) for FY 2025.
Business Highlights
- Strategic pivot: The company transitioned from a clinical-stage FXR developer to VivoSim Labs, focusing on 3D human liver and intestinal NAM-based toxicology services.
- Revenue mix: Royalty revenue remained steady after product sales ceased following the end of Mosaic operations; future revenue is expected from service contracts and custom toxicology offerings.
- Commercial validation: Data presented at May 2025 Digestive Disease Week showed 87.5% sensitivity and 100% specificity for liver toxicity predictions, supporting differentiation in the toxicology market.
- Monetization milestone: The company sold its FXR program in March 2025 for $10M upfront with up to $50M in milestones; it received a $5M milestone payment in July 2026 to fund reinvestment into the service rollout.
- Cost and operations: Management reduced headcount in R&D and SG&A, cut R&D spending by 17% year-over-year, and increased consulting spend to expand commercial service capabilities.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.